Efficacy and safety of HSK21542 for pruritus management in hemodialysis patients: a multicenter, randomized, double-blind, placebo-controlled trial
Authors:
Open Access
- 24 June 2025
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1583515
Abstract
Background: Chronic kidney disease-associated pruritus (CKD-aP) is a common and distressing symptom in hemodialysis patients. This Phase II trial evaluated the efficacy and safety of HSK21542, a selective kappa-opioid receptor agonist, in managing CKD-aP.Methods: Adult patients on hemodialysis with moderate to severe pruritus, were randomized 1:1:1 to placebo, or HSK21542 (0.3 μg/kg or 0.6 μg/kg) administered thrice weekly post-dialysis for 12 weeks. The primary endpoint was the change from baseline in the weekly mean of the worst itching intensity Numerical Rating Scale (WI-NRS) score at week 12. Secondary endpoints included quality-of-life assessments, safety evaluations, and pharmacokinetic properties.Results: A total of 90 patients were enrolled. At week 12, mean changes in WI-NRS scores from baseline were −2.94 for the placebo group, −3.40 for the 0.3 μg/kg HSK21542 group, and −2.21 for the 0.6 μg/kg HSK21542 group. The percentages of patients who had a reduction of 3 points or above in their WI - NRS scores were 44.4% in the placebo group, 62.1% in the 0.3 μg/kg HSK21542 group, and 37.0% in the 0.6 μg/kg HSK21542 group. The 0.30 μg/kg HSK21542 group demonstrated more significant improvements in Skindex - 16 scores compared to the placebo. The 5-D Itch Scale scores also presented similar trends. Both the 0.3 μg/kg and 0.6 μg/kg doses of HSK21542 were well - tolerated, with no dose-dependent adverse effects.Conclusion: The 0.3 μg/kg dose of HSK21542 demonstrated superior efficacy and safety in reducing pruritus and improving quality of life in hemodialysis patients.Keywords
This publication has 37 references indexed in Scilit:
- Psychodermatology of Chronic Pruritus: An Overview of the Link Between Itch and DistressDermatology and Therapy, 2024
- A phase 2 study of oral difelikefalin in subjects with chronic kidney disease and moderate-to-severe pruritusJournal of the American Academy of Dermatology, 2023
- Efficacy of Difelikefalin for the Treatment of Moderate to Severe Pruritus in Hemodialysis Patients: Pooled Analysis of KALM-1 and KALM-2 Phase 3 StudiesKidney Medicine, 2022
- Efficacy and Safety of Difelikefalin in Japanese Patients With Moderate to Severe Pruritus Receiving HemodialysisJAMA Network Open, 2022
- A Narrative Review of Management Strategies for Common Symptoms in Advanced CKDKidney International Reports, 2021
- Self-reported Pruritus and Clinical, Dialysis-Related, and Patient-Reported Outcomes in Hemodialysis PatientsKidney Medicine, 2021
- CKD-Associated Pruritus: New Insights Into Diagnosis, Pathogenesis, and ManagementKidney International Reports, 2020
- Randomized Controlled Trial of Difelikefalin for Chronic Pruritus in Hemodialysis PatientsKidney International Reports, 2020
- Anxiety and Depression Effects During Drug Provocation TestThe Journal of Allergy and Clinical Immunology: In Practice, 2018
- Biased ligands at G-protein-coupled receptors: promise and progressTrends in Pharmacological Sciences, 2014